Article

Antileishmanial, Antimicrobial and Antifungal Activities of Some New Aryl Azomethines

Yasser M.S.A. Al-Kahraman [1], Hassan. M.F. Madkour [1,2], Dildar Ali [1] and Masoom Yasinzai [1,]*

[1] Institute of Biochemistry, University of Balochistan, Quetta, Pakistan
[2] Synthetic Organic Chemistry Lab., Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt

* Author to whom correspondence should be addressed; E-Mail: yasinzai_masom@yahoo.com.

Abstract: A series of eighteen azomethines has been synthesized by the reaction of appropriate primary aromatic amines with aryl and/or heteroaryl carboxaldehydes. The synthesized azomethines have been evaluated for their *in vitro* antileishmanial, antibacterial and antifungal activities. The results revealed some antifungal activity of most of the synthesized compounds, whereas the antileishmaniasis activity results highlighted that all synthesized azomethines inhibited parasite growth and most of them showed highly potent action towards *Leishmania major* promastigotes. No remarkable bactericidal activities were observed.

Keywords: azomethines; primary aromatic amines; hetaryl carboxyladehyes; antileishmanial activity; antifungal activity; antibacterial activity

Introduction

Although the last century has been characterized by a drastic lowering in the mortality caused by infectious diseases, some diseases still represent a dreadful menace to human health and therefore, for a more efficient control, require the steady development of new, more powerful and inexpensive drugs. Leischmaniasis, considered a serious public health concern in many countries, is one of these diseases. It is now endemic in many parts of Pakistan and Balochistan and the Upper Sindh are vulnerable to cutaneous leishmaniasis. The World Health Organization (WHO) has identified leishmaniasis as a

major and increasing public health problem [1]. In spite of the social and economic importance of leishmaniasis as a tropical infectious disease, efforts directed towards the discovery of new drugs against it remain undeveloped [2,3]. Moreover, the drugs currently in use are expensive, require long-term treatment [4], display high liver and heart toxicities, develop clinical resistance after few weeks of treatment and currently contribute to increase leishmaniasis-AIDS co-infections in some countries [5,6]. Azomethines are characterized by the –CH=N- (imino group) which has special importance in elucidating the mechanism of transmination and racemization in biological system [7–9]. Azomethines have high potential chemical permutation possibilities and show diuretic [10], anticancer [11–14], antibacterial [15–19], and antifungal activities [20–22]. This class of compounds has also exhibited activity against a wide range of organisms and is known to have medicinal importance and is used in drug design [23–25]. It has been also reported that when some aldehydes were functionalized by condensation with various amines, the resulting azomethines had antiparasitic activities [26].

Results and Discussion

The present work is a continuation of our ongoing programme devoted to the utilization of simple and readily obtainable materials in the synthesis of different biologically active compounds [27–33], aiming at the same time to seek a cure for the cutaneous antileishmaniasis facing our society in Pakistan by presenting some cheap azomethines that might be useful in antileishmanial and antifungal drug development.

Reaction of various substituted anilines with aromatic and/or heterocyclic aldehydes in hot methanol containing a catalytic amount of glacial acetic acid afforded the target azomethines **1-18** in good yields (55–87%). (cf. Scheme 1).

The structural features of the synthesized azomethines were determined from the corresponding IR, ^{1}H-NMR, ^{13}C-NMR and mass spectroscopy data, listed in Tables 1-4. All compounds showed in the IR spectra a strong absorption band at 1,592–1,637 cm^{-1}, typical of the stretching vibrations of the C=N functionality, as well as the bands corresponding to C-H stretching vibrations.

The ^{1}H-NMR spectra of compounds **1-18** contained multiple signals in the δ 6.90 to 8.08 ppm regions due to aromatic protons and a singlet at 8.43-9.75 ppm from the C-H protons of the CH=N groups. In the spectra of compounds **5**, **6**, **11**, **12**, **13** and **14**, signals between δ 3.50 and 4.0 ppm were attributed to –OCH$_3$ groups. The signals at δ 2.36 and 2.33 ppm which appeared as singlets in compounds **15** and **16** were assigned for methyl groups. In the DEPT spectra of compounds **1-18**, there are no peaks at 189.0-196.0 ppm due to CHO group and the observed peaks were shifted to ~160.0-163.0 ppm which were attributable to HC=N group.

Scheme 1. General synthetic route.

Scheme 1. *Cont*.

Compd. No.	Ar	R_1	R_2	R_3
1	$C_6H_4(Cl)$-4	H	H	H
2	$C_6H_4(Cl)$-4	H	H	NO_2
3	[furan-2-yl-methyl structure]	H	H	H
4	[furan-2-yl-methyl structure]	H	H	NO_2
5	$C_6H_3(OH)(OCH_3)$-3,4	H	H	NO_2
6	$C_6H_3(OH)(OCH_3)$-3,4	H	H	H
7	$C_6H_5CH=CH$-	H	H	NO_2
8	$C_6H_5CH=CH$-	H	H	H
9	$C_6H_4(OH)$-2	H	H	NO_2
10	$C_6H_4(Cl)$-4	-CH=CH-CH=CH-	H	
11	$C_6H_3(OH)(OCH_3)$-3,4	-CH=CH-CH=CH-	H	
12	$C_6H_4(Cl)$-4	H	H	OCH_3
13	$C_6H_3(OH)(OCH_3)$-3,4	H	H	OCH_3
14	$C_6H_4(OH)$-2	H	H	OCH_3
15	$C_6H_4(Cl)$-4	H	H	CH_3
16	$C_6H_4(OH)$-2	H	H	CH_3
17	$C_6H_5CH=CH$-	H	H	CH_3
18	[thiophen-2-yl-methyl structure]	H	H	NO_2

Table 1. Physical and select IR data of the synthesized azomethines **1-18**.

Compd.	Color	Molecular[a] formula (Mol. Mass)	Mp (°C) (recryst. solvent)[b]	Yield (%)	IR (cm^{-1})		
					N=C	Azomethine C-H	Substituent
1	Pale yellow	$C_{13}H_{10}ClN$ [34] (215.05)	72-4 (L.P)	82	1621	2874, 1352	-
2	Yellow	$C_{13}H_9ClN_2O_2$ [35] (260.04)	140-42 (L.P)	74	1625	1333	1505, 1376(NO_2)
3	Brown	$C_{11}H_9NO$ [36] (171.07)	106 d (B)	79	1605	2850, 1328	3360(OH)
4	Brown	$C_{11}H_8N_2O_3$ [37] (216.05)	196-98 (EtOH)	68	1592	1285	1535, 1339(NO_2)
5	Pale orange	$C_{14}H_{12}N_2OH$ (272.08)	148-50 (L.P)	64	1628	1325	3354–3480(OH) 1544, 1342 (NO_2)
6	Pale yellow	$C_{14}H_{13}NO_2$ (227.09)	155-57 (L.P)	72	1621	1388	3088 broad(OH)
7	Orange	$C_{15}H_{12}N_2O_2$ (252.09)	133d (MeOH)	65	1592	1300	1512, 1335(NO_2)

Table 1. *Cont*.

8	Pale brown	$C_{15}H_{13}N$ (207.10)	100-02 (MeOH)	66	1623	1375	-
9	Orange	$C_{13}H_{10}N_2O_3$ (242.07)	162-64 (L.P)	59	1632	1338	1562, 1347 (NO_2), 3150 (OH)
10	Pale brown	$C_{17}H_{12}ClN$ (265.07)	107-09 (MeOH)	78	1637	1391	-
11	Brown	$C_{18}H_{15}NO_2$ (277.11)	114-16 (B)	76	1621	1381	3048(OH)
12	Pale Brown	$C_{14}H_{12}ClNO$ (245.06)	136-37 (MeOH)	87	1629	2838, 1364	2838, 2895 (CH_3)
13	Pale Brown	$C_{15}H_{15}NO_3$ (257.11)	257-59 (MeOH)	70	1621	2954, 1378	3000 (broad OH), 2954, 2982 (CH_3)
14	Greenish White	$C_{14}H_{13}NO_2$ (227.09)	85-87 (MeOH)	67	1637	2964, 1362	3610(OH), 2964, 2996 (CH_3)
15	White	$C_{14}H_{12}ClN$ (229.07)	127-29 (MeOH)	79	1622	2929, 1354	2854, 2925 (CH_3)
16	White	$C_{14}H_{13}NO$ (211.10)	96-98 (MeOH)	67	1615	2920, 1366	3100 (OH), 2920 (CH_3)
17	Pale Orange	$C_{16}H_{15}N$ [38] (221.12)	76-77 (MeOH)	71	1627	2912, 1379	2912 (CH_3)
18	Pale Yellow	$C_{11}H_8N_2O_2S$ [39] (232.03)	135-37 (MeOH)	55	1612	1323	1543, 1341 (NO_2)

[a] references are given for known products, the others are new; [b] L.P = Light Petroleum b.p. 60–80 °C, B = benzene, EtOH = ethanol, MeOH = methanol.

Table 2. ^{1}H-NMR of azomethines **5-16** (DMSO-d_6) (δ, ppm).

Compd.	^{1}H-NMR
5	9.45 (s, 1H, -OH, exchangeable), 8.36 (s, 1H, benzylidenimine H), 8.08-6.90 (m, 7H, Ar-H), 3.80 (s, 3H, -OCH$_3$).
6	9.75 (s, 1H, -OH, exchangeable), 8.43 (s, 1H, -CH=N), 7.52-6.88 (m, 8H, Ar-H), 3.84 (s, 3H, -OCH$_3$).
7	8.10 (m, 1H, -CH=N), 7.60-6.95 (m, 11H, Ar-H and olefinic H).
8	8.25 (d, 1H, benzylideimin H, *J* = 5.36 Hz), 7.54-7.07 (m, 12H, Ar-H and olefinic H).
9	12.27 (s, 1H, OH, exchangeable), 8.99 (s, 1H, -CH=N), 8.32-6.98 (m, 7H, Ar-H).
10	8.73 (s, 1H, benzylidenimine H), 8.09-7.23 (m, 11H, Ar-H).
11	9.76 (s, 1H, OH, exchangeable), 8.53 (s, 1H, benzylidenimine H), 8.29-6.92 (m, 10H, Ar-H), 3.89 (s, 3H, -OCH$_3$).
12	8.64 (s, 1H, -CH=N), 7.93-6.97 (m, 8H, Ar-H), 3.77 (s, 3H, -OCH$_3$).
13	9.60 (s, 1H, OH, exchangeable), 8.44 (s, 1H, -CH=N), 7.49-6.86 (m, 7H, Ar-H), 3.83 and 3.76 (2s, 6H, 2 -OCH$_3$).

Table 2. *Cont*.

14	13.38 (s, 1H, OH, exchangeable), 8.59 (s, 1H, benzylidenimine H), 7.36-6.89 (m, 7H, Ar-H), 3.82 (s, 3H, -OCH₃)
15	8.41 (s, 1H, -CH=N),7.83-7.11 (m, 8H, Ar-H), 2.36 (s, 3H, -CH₃)
16	13.19 (s, 1H, OH, exchangeable), 8.94 (s, 1H, -CH=N), 7.63-6.93 (m, 7H, Ar-H), 2.33 (s, 3H, -CH₃).

Table 3. ^{13}C-NMR (DMSO-d$_6$) (δ, ppm) of azomethines **5-16**.

Compd	^{13}C-NMR
5	160.0, 154.2, 152.4, 147.3, 146.3, 131.0, 125.5, 125.2, 123.2, 115.9, 112.3, 56.1.
6	160.2, 152.4, 152.0, 147.3, 131.1, 129.9, 127.2, 125.5, 122.3, 115.9, 112.3, 56.1.
7	163.7, 158.6, 146.4, 135.2, 133.3, 128.5, 128.5, 127.9, 125.2, 123.2, 119.8.
8	163.7, 152.4, 135.2, 133.3, 130.0, 128.6, 128.5, 127.9, 127.2, 122.3, 119.9.
9	161.1, 160.0, 154.2, 146.4, 132.4, 132.1, 125.2, 123.2, 121.4, 120.5, 117.8.
10	160.0, 151.9, 136.6, 135.0, 134.5, 130.5, 128.9, 128.6, 128.3, 127.8, 126.8, 126.3, 115.2.
11	160.0, 152.2, 151.9, 147.9, 147.3, 135.0, 131.1, 128.5, 128.3, 127.8, 126.7, 126.3, 125.5, 115.9, 115.1, 112.3, 56.1.
12	160.0, 159.1, 144.3, 136.5, 134.5, 130.6, 128.8, 122.1, 115.6, 55.8.
13	159.9, 159.1, 152.4, 147.3, 144.3, 131.1, 125.5, 115.9, 115.6, 122.1, 112.3, 56.1, 55.8.
14	161.1, 160.1, 159.1, 144.3, 132.4, 132.1, 122.1, 121.4, 120.4, 117.8, 115.5, 55.8.
15	160.1, 149.1, 136.9, 136.5, 134.5, 130.6, 130.3, 128.9, 122.2, 21.3.
16	161.1, 159.9, 149.1, 136.8, 132.4, 132.1, 130.3, 122.2, 121.4, 120.5, 117.7, 21.3.

Table 4. Mass spectra of azomethines **5-16**.

Compd.	m/z (% Relative abundance)
5	272 (M$^{+\cdot}$, 4.25), 227 (2.34), 139 (4.85), 138 (70.25), 107 (76.60), 92 (48.80), 91 (6.91), 65 (100.00).
6	227 (M$^{+\cdot}$, 98.26), 211 (21.66), 166 (14.45), 154 (7.12), 139 (5.12), 104 (22.42), 77 (100.00)
7	252 (M$^{+\cdot}$, 27.28), 251 (M-1$^{\rceil+\cdot}$, 83.41), 205 (56.73), 178 (4.88), 149 (4.88), 138 (54.55), 115 (70.16), 92 (48.50), 91 (47.95), 65 (100.00)
8	207 (M$^{+\cdot}$, 33.52), 206 (M-1$^{\rceil+\cdot}$, 100.00), 178 (3.25), 128 (13.57), 115 (18.72), 77 (90.33).
9	242 (M$^{+\cdot}$, 96.65), 212 (13.38), 195 (37.11), 167 (29.72), 151 (5.91), 120 (44.48), 76 (100.00)
10	267 (M+2$^{\rceil+\cdot}$, 20.42), 266 (M+1$^{\rceil+\cdot}$, 20.79), 265 (M$^{+\cdot}$, 60.68), 230 (2.89), 202 (3.48), 154 (23.00), 127 (100.00), 77 (29.47), 51 (9.14).
11	277 (M$^{+\cdot}$, 100.00), 261 (7.13), 216 (6.07), 204 (5.90), 178 (3.99), 154 (19.97), 127 (80.53), 101 (11.97), 85 (44.01), 83 (69.57), 77 (27.60).
12	247 (M+2$^{\rceil+\cdot}$, 26.19), 246 (M+1$^{\rceil+\cdot}$, 15.23), 245 (M$^{+\cdot}$, 77.99), 230 (100.00), 201 (10.17), 167 (27.80), 149 (5.64), 139 (10.67), 114 (4.26), 77 (35.29), 63 (45.11).
13	257 (M$^{+\cdot}$, 100.00), 242 (85.72), 227 (3.73), 198 (5.24), 170 (15.75), 154 (7.33), 134 (6.16), 115 (7.02), 77 (4.02), 64 (19.33).
14	228 (M+1$^{\rceil+\cdot}$, 16.62), 227 (M$^{+\cdot}$, 100.00), 212 (71.79), 183 (4.33), 154 (3.40), 128 (5.33), 105 (3.08), 77 (55.04), 65 (38.15).
15	231 (M+2$^{\rceil+\cdot}$, 30.49), 230 (M+1$^{\rceil+\cdot}$, 33.41), 229 (M$^{+\cdot}$, 90.60), 193 (2.89), 165 (4.57), 150 (2.05), 118 (22.99), 91 (100.00), 77 (9.79), 65 (61.60).
16	211 (M$^{+\cdot}$, 100.00), 210 (M-1$^{\rceil+\cdot}$, 76.87), 167 (6.29), 120 (12.86), 118 (8.68), 91 (80.65), 65 (74.49).

Antileishmaniasis activity

Antileishmanial activity of the compounds (1-18) was assayed by Zhai's method [40] using a pre-established culture of *L. major* (Table 5) Parasites were cultured in medium M199 with 10% foetal bovine serum; 25 mM of HEPES, and 0.22 µg of penicillin and streptomycin, respectively, at 24 °C in a shaking incubator. Compounds **1, 6** and **16** have moderate activity against *L major*. Azomethines **4, 10, 14, 15,** and **17** show good activity against *L major* and azomethines **9** and **12** show significant activity. The high *in vitro* antileishmaniasis activity of these compounds makes them promising leads for development of effective therapeutic agents.

Table 5. % Inhibition of azomethines against *L. major* leishmania.

Compound	*L. major* [a]
1	0.77 ± 0.09
2	-
3	-
4	0.65 ± 0.01
5	-
6	0.73 ±0.16
7	-
8	-
9	0.59 ± 0.07
10	0.61 ± 0.27
11	-
12	0.57 ±0.11
13	0.63 ± 0.04
14	0.68 ±0.12
15	0.66 ±0.18
16	0.81 ± 0.03
17	0.62 ± 0.08
18	-
Standard Drug IC$_{50}$ (µg/mL± S.D)	
Amphotericin B	0.56 ± 0.20

[a] percentage inhibition activity: 100 = (non-significant; 0.95−0.80 = low; 0.79−0.70 = Moderate; 0.69−0.60 = Good; below 0.59-0.56 = Significant activity).

Antifungal activity

The antifungal bioassay is screened by the Agar Tube Dilution Method [41–42], in which the test compounds were screened for activity against the following organisms: *Candida albicans, Aspergillus flavus, Microsportum canis, Fusarium solani* and *Candida glabrata*. Table 6 shows % inhibition of the synthesized azomethines. In all tests the linear growth in control was 100 mm. It is evident from the antifungal screening that:

    (i)   None of the compounds are inactive against *C. albicans* or *C. glabrata.*

    (ii) Only compound **17** has moderate activity against *A. flavus*.

(iii) Azomethines **4, 5, 12** and **14** have low activity against *M. canis*, whereas compound **9** has good antifungal activity against the same fungus.

(iv) Azomethine **9** shows moderate activity against *F. solani*, whereas azomethines **4, 11, 17** and **18** have low activity against the same fungus.

Table 6. % inhibition of azomethines against different types of fungi.

Compound	*C. albicans*	*A. flavus*	*M. canis*	*F. solani*	*C. glabrata*
1	0	0	0	0	0
2	0	0	0	0	0
3	0	0	0	0	0
4	0	0	20[a]	35	0
5	0	0	30	0	0
6	0	0	0	0	0
7	0	0	0	0	0
8	0	0	0	0	0
9	0	0	60	40	0
10	0	0	0	0	0
11	0	0	0	35	0
12	0	0	35	0	0
13	0	0	0	0	0
14	0	0	20	0	0
15	0	0	0	0	0
16	0	0	0	0	0
17	0	40	0	15	0
18	0	0	0	20	0
Std. Drug MIC (mg/mL)					
Miconazole	110.8	-	98.4	73.25	110.28
Amphotericin B	-	20.0	-	-	-

[a] percentage inhibition activity: 0-39 = low (non-significant); 40-59 = Moderate; 60-69 = Good; Above 70 = Significant activity.

Antibacterial activity

The antibacterial activity of the synthesized azomethines was screened by the agar well diffusion method [43–44] against Gram-negative and Gram-positive bacteria, namely *Escherchia coli*, *Bacillus subtilis*, *Shigella flexen ari*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Salmonella typhi*. Only compound **4** showed significant activity (25 mm inhibition zone) against *E. coli* and moderate activity (14 mm zone) against *B. subtilis*.

Experimental

General

All aromatic and heterocyclic aldehydes as well as primary aromatic amines were obtained commercially from the Aldrich Chemical Company. Solvents used were of analytical grade. M.p. were measured using a Stuart (UK) electric melting point apparatus. IR spectra were recorded with a Thermo 330 FTIR spectrometer. Mass spectra were measured on a MAT 312 Finnigan instrument

operating at 70 eV. ^{1}H- and ^{13}C-NMR spectra were recorded on a Avance 400 Bruker instrument using TMS as internal standard and DMSO-d$_6$ as solvent.

Chemistry: General procedure for synthesis of azomethines

An equimolar mixture of aryl and/or hetaryl carboxaldehyde with selected primary aryl amine in methyl alcohol (30 mL) containing few drops of glacial acetic acid was heated to reflux temperature for 3-4 hours then left overnight until the product precipitated. The product was filtered off, washed with light petroleum and recrystallized from the suitable solvent [cf. Table 1]. It is worthy to mention that anhydrous dry solvents for recrystallization were essential to avoid decomposition by hydrolysis. The crystalline solid that separated out was filtered by suction using water pump and washed with light petrol to afford the desired azomethines **1-18** in pure state.

Biological Screening: Antileishmaniasis Activity - Preparation of Samples

Each compound (1 mg) was dissolved in DMSO (1 mL) and Amphotercin B (1 mg) was also dissolved in DMSO (1 mL) as positive control. Parasites at log phase were centrifuged at 3,000 rpm for 3 minutes. Parasites were diluted in fresh culture medium to a final density of 2×10^6 cells/mL. In 96-well plates, 180 µL of medium was added in different wells. Twenty µL of the compound was added in medium and serially diluted. Parasite culture (100 µL) was added in all wells. Three rows were left for negative and positive controls. In the negative controls, DMSO was serially diluted in medium while the positive control contained varying concentrations of the standard antileishmanial compound Amphotercin B. The plates were incubated for 72 hours at 24 °C. The culture was examined microscopically on an improved neubaur counting chamber and IC$_{50}$ values of compounds possessing antileishmanial activity were calculated. All assays were run in duplicate. IC$_{50}$ of samples was determined by using the Prism software.

Antifungal activity

The concentration of the tested compounds was 200 ug/mL of DMSO. A reference antifungal and DMSO were used as positive and negative control, respectively. Incubation temperature was 27 °C and time 7 days. The inculation of fungus was carried out with a 4 mm diameter piece of fungus removed from a seven-day-old culture. The growth in the compound-amended media was determined by measuring linear growth (mm) and growth inhibition calculated with reference to the negative control and calculating the % inhibition of fungal growth:

$$\% \text{ Inhibition} = 100 - \frac{\text{linear growth in test (mm)}}{\text{linear growth in control (mm)}} \times 100$$

Antibacterial Activity

The concentration of tested compound was 1 mg/mL of DMSO, whereas the concentration of the reference antibacterial drug imipenem was 10 mg/disc. Blank test showed that DMSO in the preparations of the test solutions does not affect the test organisms.

Conclusion

Eighteen azomethines were prepared by reacting an aromatic or heterocyclic aldehyde and an aromatic primary amine compound in a protic solvent like ethanol or methanol heated to reflux temperature in presence of few drops of acetic acid as a catalyst. The acidic catalyst leads to the increase of the electrophilicity of the caronyl function of the carboxalehyde containing reactant. The results revealed some order of fungicidal activities of most of the synthesized compounds whereas the results of leishmanicidal activity highlighted that all synthesized azomethines inhibited the growth of parasite and most of them showed high potent action towards leishmania major promastigotes. No remarkable bactericidal activities have been recorded. Azomethines are characterized by the –CH=N- (imino group) which has special importance in elucidating the mechanism of transmination and racemization in biological system. Azomethines have high potential chemical permutation and show diuretic, anticancer, antibacterial, and antifungal activities. This class of compounds also exhibited activity against a wide range of organisms and are known to have medicinal importance and used in drugs design. It has been also reported that some aldehydes when were functionalized by condensation with various amines, the produced azomethines had antiparasitic activities. It is evident that Azomethine compounds **1, 6** and **16** have moderate activity against *L major*. Azomethines **4, 10, 14, 15,** and **17** show good activity against *L major* and azomethine **9** and **12,** shows significant activity against *L.major*. The high *in vitro* Anti leishmaniasis activity of these compounds makes them a promising lead for development of effective therapeutic agents.It is clear that the synthesize of Azomethines showed only compound 17 has moderated activity against A flavus. Azomethine 4,5,12 and 14 have low activity against M. Canis whereas compound 9 has good anti fungal activity against same fungus. Azomethine 9 shows a moderate activity against F. Solani whereas azomehtines 4,11,17 and 18 have low activity against the same fungus. In bacteria among the 18 synthesize of azomethines tested only compound 4 showed significant activity against E.coli and low activity against B. subtilis.

Acknowledgments

References

1.   Modabber, F. Tropical Disease Research Progress Leishmaniasis. In *Tropical Disease Research Progress 1991–1992*; World Health Organization: Geneva, Switzerland, 1993; pp. 77–87.
2.   Croft, S.L. The current status of antiparasite chemotherapy. *Parasitology* **1997**, *114*, 3–15.
3.   Engers, H.D.; Bergquist, R.; Modabber, F. Progress on vaccines against parasites. *Dev. Biol. Stand.* **1996**, *87*, 73–84.
4.   Murray, H.W. Treatment of visceral leishmaniasis in 2004. *Am. J. Trop. Med. Hyg.* **2004**, *71*, 787–794.
5.   Croft, S.L. Recent developments in the chemotherapy of leishmaniasis. *Trends Pharmacol. Sci.* **1988**, *9*, 376–381.

6. Berman, J.D. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. *Rev. Infect. Dis.* **1988**, *10*, 560–586.

7. Lau, K.Y.; Mayr, A.; Cheung, K.K. Synthesis of transition metal isocyanide complexes containing hydrogen bonding sites in peripheral locations. *Inorg. Chim. Acta.* **1999**, *285*, 223–232.

8. Ispir, E.; toroglu, S.; karyaldiz, A. Synthesis, characterization, antimicrobial and genotoxic activities of new Schiff bases and their complexes. *Transition Met. Chem.* **2008**, *33*, 953–960.

9. Ispir, E.; Kurtoglu, M.; Purtas, F. Synthesis and antimicrobial activity of new Schiff bases having the –SiOR group (R=CH$_3$ or CH$_2$CH$_3$), and their transition metal complexes. *Trans. Met. Chem.* **2005**, *30*, 1042–1047.

10. Supuran, C.T.; Barboiu, M.; Luca, C.; Pop, E.; Brewster, M.E.; Dinculescu, A. Carbonic anhydrase activators. Part 14. Syntheses of mono and bis pyridinium salt derivatives of 2-amino-5-(2-aminoethyl)- and 2-amino-5-(3-aminopropyl)-1,3,4-Thiadiazole and their interaction with isozyme II. *Eur. J. Med. Chem.* **1996**, *31*, 597–606.

11. Sharma, K.P.; Jolly, V.S.; Phatak, P. Schiff bases and their derivatives as potential anticancer agents. *Ultra Scient. Phys. Sci.* **1998**, *10*, 263–266.

12. Kuzamin, V.E.; Artemenko, A.G.; Lozytska, R.N.; Fedtchouk, A.S.; Lozitsky, V.P.; Muratov, E.N.; Mescheriakov, A.K. Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure. *SAR QSAR Environ. Res.* **2005**, *16*, 219–230.

13. Shingare, M.S.; Ingle, D.B. Synthesis of pyrimidine Schiff bases as anticancer agents. *J. Indian Chem. Soc.* **1976**, *53*, 1036–1037.

14. Shkawat, D.R.; Sabins, S.S.; Deliwala, C.V. Potential anticancer agents, Schiff bases from *p*-(3-azaspiro[5,5]undec-3-yl)benzaldehydes. *Bull. Haffkine Inst.* **1973**, *1*, 35–39.

15. More, S.V.; Dongarkhadekar, D.V.; Chavan, R.N.; Jadhav, W.N.; Bhusare, S.R.; Pawar, R.P. Synthesis and antibacterial activity of new Schiff bases, 4-thiazolidinones and 2-azetidinones. *J. Indian Chem. Soc.* **2002**, *79*, 768–769.

16. Bhendkar, A.K.; Vijay, K.; Raut, A.W. Synthesis of some novel Schiff bases of 2-aminopyrimidine and their antimicrobial activity. *Acta Ciencia India Chem.* **2004**, *30*, 29–32.

17. Vaghasiya, Y.K.; Nair, R.S.; Baluja, M.; Chanda, S.S. Synthesis, structural determination and antibacterial activity of compounds derived from vanillin and 4-aminoantipyrine. *J. Serb. Chem. Soc.* **2004**, *69*, 991–998.

18. Vashi, K.; Naik, H.B. Synthesis of novel Schiff base and azetidinone derivatives and their antibacterial activity. *Eur. J. Chem.* **2004**, *1*, 272–276.

19. Rhodes, R.C.; Hall, H.; Beesley, S.R.; Jenkins, J.G.; Collins, D.C.; Zheng, P. Therapeutic Potentiation of the immune system by costimulatory Schiff base-forming drugs. *Nature* **1995**, *377*, 71–75.

20. Safwat, H.M.; Ragab, F.A.; Eid, N.M.; Abdel, G.M. Synthesis, anti-tumor and antimicrobial activities of 3-chloro-9- (*p-N*-substituted sulfamoylphenylaminoethylene) acridines. *Egyptian J. Pharm. Sci.* **1988**, *29*, 99–110.

21. Mtrei, R.; Yadawe, M.; Patil, S.A. Synthesis of biologically active p-bis(amino-5-mercapto-1,2,4-triazol-3-yl)benzene and its Schiff base: a new class of bis-triazole. *Orient. J. Chem.* **1996**, *12*, 101–102.

22. Hossain, M.E.; Allam, M.N.; Begum, J.; Akbar, M.A.; Uddin, M.N.; Smith, F.E.; Hynes, R.C. The preparation, characterization, crystal structure and biological activities of some Cu(II) complexes of the 2-benzoyl pyridine Schiff bases of *S*-methyl-and *S*-benzyldithiocarbazate. *Inorg. Chim. Acta.* **1996**, *249*, 207–213.

23. Khan, S.A.; Siddiqui, A.A.; Shibeer, B. Analgesic activity of isatin derivatives. *Asian J. Chem.* **2002**, *14*, 1117–1118.

24. Verma, M.; Pandeya, S.N.; Singh, K.N.; Stables, J.P. Anticonvulsant activity of Schiff bases of isatin derivatives. *Acta Pharm.* **2004**, *54*, 49–56.

25. Sari, N.; Arslan, S.; Logoglu, E.; Sakiyan, L. Antibacterial Activities of some Amino acid-Schiff bases. *GUJ Sci.* **2003**, *16*, 283–288.

26. Rathelot, P.; Azas, N.; El-Kashef, H.; Delmas, F.; Di Giorgio, C.; Timon-David, P.; Maldonado, J.; Vanelle, P. 1,3-Diphenylpyrazoles: synthesis and antiparasitic activities of azomethine derivatives. *Eur. J. Med. Chem.* **2002**, *37*, 671–679.

27. Madkour, H.; Farag, A.; Ramses, S.; Ibrahiem, N. Synthesis and fungicidal activity of new imidazoles from 2-(chloromethyl)-1 H –benzimidazole. *Phosphor. Sulfur Phosphorous Silicon* **2006**, *181*, 255–265.

28. Madkour, H.M.F. Afify, A.A.E. Abdalha, A.A. Elsayed, G.A.; Salem, M.S. Synthetic utility of enaminonitrile moiety in heterocyclic synthesis: Synthesis of some new thienopyrimidines. *Phosphor. Sulfur Phosphorous Silicon* **2009**, *184*, 719–732.

29. Nofal, Z.M.; El-Zahar, M.I.; Salem, M.A.I.; Madkour, H.M.F. Synthesis and chemoprophylactic effect of novel coumarin derivatives. *Egypt J. Chem.* **2005**, *48*, 587–604.

30. Madkour, H.M.F.; Mahmoud, M.R.; Sakr, A.M.; Habashy, M.M. Synthesis and antibacterial activity of new 4H-pyrano [3,2-h]quinolines and fused derivatives. *Sci. Pharm.* **2001**, *69*, 33–52.

31. Madkour, H.M.F.; Salem, M.A.I.; Soliman, E.A.; Mahmoud, N.F.H. A facile one-pot synthesis and antibacterial activity of aziridines and thiazines from 1,3-diarylprop-2-enones. *Phosphor. Sulfur Phosphorous Silicon* **2001**, *170*, 15–28.

32. Salem, M.A.I.; Madkour, H.M.F.; Soliman, E.A.; Mahmoud, N.F.H. Synthesis of bactericides via carbon nucleophilic addition on 1,3-diarylprop-2-enones as michael acceptors. *Heterocycles* **2000**, *53*, 1129–1143.

33. Mahmoud, M.R.; Madkour, H.M.F. Reactions of 3-3-chlorophenyl-1-4-(3,4-methylenedioxybenzylidene)aminophenylprop-2-enone with some nucleophiles. *Synth. Commun.* **1996**, *26*, 3799–3808.

34. Sobanov, A.A.; Zolotukhin, A.V.; Galkina, I.V.; Galkin, V.I.; Cherkasov, R.A. Kinetics and mechanism of the Pudovik reaction in the azomethine series: III. Acid-catalyzed hydrophosphorylation of imines. *Russ. J. Gen. Chem.* **2006**, *76*, 421–429.

35. Neuvonen, H.; Neuvonen, K.; Fülöp, F. Substituent cross-interaction effects on the electronic character of the C=N bridging group in substituted benzylidene anilines − Models for molecular cores of mesogenic compounds. A ^{13}C-NMR study and comparison with theoretical results. *J. Org. Chem.* **2006**, *71*, 3141–3148.

36. Montalvo-Gonza´lez, R.; Ariza-Castolo, A.; Molecular structure of di-aryl-aldimines by multinuclear magnetic resonance and X-ray diffraction. *J. Mol. Struct.* **2003**, *655*, 375–389.

37. Subudhi, B.B.; Satpathy, S.; Bhatta, D.; Pradhan, D. Synthesis of some 2-(R, R')-3-(p-nitro phenyl)-thiazolidinone as potent antifungal agents. *J. Teach. Res. Chem*. **2005**, *12*, 42–45.

38. Sain, B.; Thyagarajan, G.; Sandhu, J.S. Cycloaddition reactions of *meso*-ionic oxazolone with cinnamaldehyde anils. *Can. J. Chem.* **1980**, *58*, 2034–2037.

39. Youssef, M.S.K. Synthesis of antimicrobial heteroaryl-substituted-1,2,3-triazolines via the reaction of diazomethane with anils and mixed azines of thiophenealdehyde and/or isatin. *J. Chem. Technol. Biotechnol.* **1981**, *31*, 363–367.

40. Zhai, L.; Chen, M.; Blom, J.; Teander, T.G.; Christensen, S.B.; Karazmi, A. The antileishmanial acitivity of novel oxygenated chalcones and their mechanism of action. *Antimicrob. Agents Chemother.* **1999**, *43*, 793–803.

41. Choudhary, M.I.; Dur-e-Shahwar Parveen, Z.; Jabbar, A.; Ali, I.; Atta-Ur-Rahman. Antifungal steroidal lactones from Withania coagulance. *Phytochemistry* **1995**, *40*, 1243–1246.

42. Janaki, S.; Vijayasekaram, V. Antifungal activities of aglaia roxburghiana (W & A). *Biomedicine*. **1998**, *18*, 86–89.

43. Alves, T.M.A.; Silva, A.F.; Brandao, M.; Grandi, T.S.M.; Smania, E.F.A.; Smania, A., Jr.; Zani, C.L. Antibacterial xanthones from Kielmeyera variabilis mart. (Clusiaceae). *Mem. Inst. Oswaldo. Cruz.* **2000**, *95*, 367–373.

44. Stepanović, S.; Antić, N.; Dakić, I.; Švabić-Vlahović, M. *In vitro* antimicrobial activity of propolis and synergism between propolis and antimicrobial drugs. *Microbiol. Res.* **2003**, *158*, 353–357.

Sample Availability: Samples of the compounds **1-18** are available from the authors.